Hims Launches At-Home Testosterone Testing and TRT Service for Men
Hims, a telehealth firm established in 2017, has introduced a testosterone replacement therapy service tailored for cisgender men. This service integrates at-home capillary blood testing with both injectable and oral treatment options. Utilizing a Tasso device, patients can gather a blood sample to evaluate 21 biomarkers, including testosterone levels. Peter Stahl, a urologist and senior VP of men's health at Hims, is focused on enhancing accessibility to testing. According to the 1990 Anabolic Steroids Control Act, testosterone prescriptions necessitate a video consultation and continuous monitoring. Mohit Khera from Baylor College of Medicine warned that such therapy may lead to infertility and is not advisable for those wishing to conceive. Hims has 2.9 million customers and initially concentrated on erectile dysfunction.
Key facts
- Hims launched a testosterone replacement therapy service for cisgender men with at-home testing
- Patients use a Tasso microneedle arm device; labs analyze 21 biomarkers
- Testosterone is a controlled substance under the 1990 Anabolic Steroids Control Act, requiring video consultations
- Peter Stahl is a urologist and senior vice president of men's health at Hims
- Mohit Khera directs Baylor College of Medicine's Laboratory for Andrology Research at McNair Medical Institute
- Hims launched in 2017 and serves 2.9 million customers as a publicly traded company
- A 2022 undercover study found six of seven digital clinics prescribed TRT despite normal levels
- Stahl said asymptomatic patients will not be prescribed testosterone on the platform
Entities
Artists
- Peter Stahl
- Mohit Khera
- Pete Hegseth
- Ken Paxton
- James Talarico
Institutions
- Hims
- Baylor College of Medicine
- McNair Medical Institute
- American Urological Association
- Tasso
- Theranos
- Pentagon
- US armed services
- Texas Republicans
Locations
- United States
- Texas